SourceOne (Chicago) has partnered with Nutri Pharmaceuticals Research (Las Vegas) to develop powder forms of Source’s products with the hopes to broaden the company’s appeal in the nutritional market.
SourceOne (Chicago) has partnered with Nutri Pharmaceuticals Research (Las Vegas) to develop powder forms of Source’s products with the hopes to broaden the company’s appeal in the nutritional market.
Both companies “share the same vision for delivering greater value and broader functionality of exceptional health and wellness ingredients and formulas through innovative application technology. We like to say that we transform good ingredients into great ingredients,” said NPRI CEO, Godfrey Yew.
This new partnership will allow SourceOne to alter the form of products like CoQsource Coenzyme Q10 and OmegaChoice Concentrated Omega-3 Essential Fatty Acids (EFAs) in free-flowing powders, using NPRI’s oil-to-powder technology, according to Jesse Lopez, SourceOne CEO.
“The synergies created by these partnerships are directly and immediately applicable to SourceOne ingredients and formulas in various forms and concentrations,” said Lopez.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.